Abstract
Psychotropic drugs, like antipsychotics and antidepressants, are often associated with metabolic side effects such as weight gain and an increased risk of the development of diabetes and an atherogenic lipid profile. These adverse effects not only bear a high cardiovascular risk and lead to higher morbidity and mortality, but are an additional burden to mentally ill patients and can be a decisive factor for the compliance and, consequently, the success of the therapy. Second generation antipsychotics (SGAs), in particular, clozapine and olanzapine, lead to significant weight gain and impair glucose metabolism. Despite the availability of newer SGAs, such as aripiprazole, which are considered to be less prone to cause metabolic side effects, olanzapine is still one of the most prescribed SGAs worldwide. Antidepressant drugs may also induce weight again and diabetes even though the literature is contradictory, probably due to different receptor affinities. This review aims to provide an overview of the metabolic side effects caused by commonly used psychotropic drugs and give insight into underlying mechanisms.
Keywords: Antidepressants, antipsychotics, diabetes, glucose metabolism, insulin resistance, psychotropic drugs, weight gain.
Current Diabetes Reviews
Title:The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Volume: 9 Issue: 5
Author(s): Ramona Al-Zoairy, Claudia Ress, Alexander Tschoner, Susanne Kaser and Christoph Ebenbichler
Affiliation:
Keywords: Antidepressants, antipsychotics, diabetes, glucose metabolism, insulin resistance, psychotropic drugs, weight gain.
Abstract: Psychotropic drugs, like antipsychotics and antidepressants, are often associated with metabolic side effects such as weight gain and an increased risk of the development of diabetes and an atherogenic lipid profile. These adverse effects not only bear a high cardiovascular risk and lead to higher morbidity and mortality, but are an additional burden to mentally ill patients and can be a decisive factor for the compliance and, consequently, the success of the therapy. Second generation antipsychotics (SGAs), in particular, clozapine and olanzapine, lead to significant weight gain and impair glucose metabolism. Despite the availability of newer SGAs, such as aripiprazole, which are considered to be less prone to cause metabolic side effects, olanzapine is still one of the most prescribed SGAs worldwide. Antidepressant drugs may also induce weight again and diabetes even though the literature is contradictory, probably due to different receptor affinities. This review aims to provide an overview of the metabolic side effects caused by commonly used psychotropic drugs and give insight into underlying mechanisms.
Export Options
About this article
Cite this article as:
Al-Zoairy Ramona, Ress Claudia, Tschoner Alexander, Kaser Susanne and Ebenbichler Christoph, The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990067
DOI https://dx.doi.org/10.2174/15733998113099990067 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice
Current Vascular Pharmacology New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry The Fetal Cardiac Function
Current Cardiology Reviews Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemoprevention of Colorectal Cancer: Ready for Routine Use?
Current Topics in Medicinal Chemistry Cardioprotective Activity of Agaricus bisporus Against Isoproterenol- Induced Myocardial Infarction in Laboratory Animals
Current Nutrition & Food Science Exploring and Prioritization of Mobile-Based Self-Management Strategies for HIV Care
Infectious Disorders - Drug Targets Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure
Current Drug Safety Recent Advances in the Oral Delivery of Insulin
Recent Patents on Drug Delivery & Formulation Anti Inflammatory and Anti Arthritic Activity of Different Milk Based Formulation of Curcumin in Rat Model
Current Drug Delivery Choice of Treatment with Antidepressants: Influencing Factors
Current Pharmaceutical Design